Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listRabeprazole

Rabeprazole

  • CAS NO.:117976-89-3
  • Empirical Formula: C18H21N3O3S
  • Molecular Weight: 359.44
  • MDL number: MFCD00868879
  • EINECS: 601-501-2
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 23:02:33
Rabeprazole Structural

What is Rabeprazole?

Absorption

Absolute bioavailability is approximately 52%.

Description

Rabeprazole, a proton pump inhibitor (PPI), effectively lowers stomach acid production to alleviate conditions such as gastroesophageal reflux disease (GERD), ulcers, and other issues caused by excessive acid production. It belongs to the benzimidazole derivative family, sharing a structural similarity with omeprazole, another PPI. Rabeprazole hampers the activity of the gastric proton pump responsible for acid production. By binding to the pump, it obstructs the release of hydrogen ions into the stomach, ultimately reducing acid production. Furthermore, rabeprazole exhibits various biochemical and physiological effects. A study conducted on rats revealed that rabeprazole effectively decreases the gastric proton pump′s activity, leading to a decrease in gastric acid secretion.

The Uses of Rabeprazole

Rabeprazole is used to treat hyperacidity. It is a proton pump inhibitor that helps heal gastrointestinal ulcers, treats gastroesophageal reflux disease, and also treats hypersecretory disorders.

Indications

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

Background

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.

What are the applications of Application

Rabeprazole is a proton pump ATP-ase inhibitor

Definition

ChEBI: Rabeprazole is a member of benzimidazoles, a sulfoxide and a member of pyridines. It has a role as an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor and an anti-ulcer drug. It is a conjugate acid of a rabeprazole(1-).

brand name

Aciphex (Eisai Medical Research) .

Mechanism of action

Rabeprazole is a proton pump inhibitor (PPI) and as such covalently binds with and inactivates the gastric parietal cell proton pump (H+/K+-ATPase). This inhibits in turn gastric acid production and raises gastric pH[1].

Pharmacokinetics

Rabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabeprazole may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H+, K+ -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.

Pharmacokinetics

Rabeprazole is marketed as an enterically coated formulation due to the instability of all PPIs in an acid environment. After oral ingestion, it is relatively rapidly absorbed as the maximal plasma concentration reaches between 2.8 and 5.1 postdose. The pharmacokinetics of the molecule is linear in the range 10–80 mg with an overall bioavailability of 52%. Rabeprazole does not have a saturable first-pass metabolism, and it can be absorbed in high doses.
Neither antacids nor food influences the bioavailability of the molecule, even if food intake delayed the absorption of rabeprazole 20 mg of about 1.7 h and reduced the apparent elimination half-life due to a probable delayed gastric emptying. Preclinical studies have demonstrated that rabeprazole’s volume of distribution is 0.34 L/kg in various tissues, including the gastric mucosa, stomach, kidney, bladder, liver, intestine, and thyroid. In healthy volunteers, it was demonstrated to be bound to 94.8%–97.5% of plasma proteins.

Side Effects

The more common side effects of rabeprazole can include: headache. pain in the abdomen (stomach area) sore throat.
The serious side effects of rabeprazole can include: has stomach cramps, bloated feeling, watery and severe diarrhea which may also be bloody sometimes, fever, nausea or vomiting, or unusual tiredness or weakness. This medicine may increase your risk of having fractures of the hip, wrist, and spine.

Drug interactions

A product that may interact with this drug is: methotrexate (especially high-dose treatment).
Some products need stomach acid so that the body can absorb them properly. Rabeprazole decreases stomach acid, so it may change how well these products work. Some affected products include ampicillin, atazanavir, erlotinib, levoketoconazole, nelfinavir, pazopanib, rilpivirine, sparsentan, certain azole antifungals (itraconazole, ketoconazole, posaconazole), among others.

Metabolism

Hepatic

Dosage

Rabeprazole is usually taken once a day. Follow all directions on the prescription label and read all dosing instructions or instruction sheets. Use the medication exactly as directed.Rabeprazole is only suitable for short-term use, usually 4 to 8 weeks. If you need additional treatment time, your doctor may recommend a second course of treatment.

References

[1] Fabio Pace. “A review of rabeprazole in the treatment of acid-related diseases.” Therapeutics and Clinical Risk Management 3 3 (2007): 363–79.

Properties of Rabeprazole

Melting point: 99-100° (dec)
Boiling point: 603.9±65.0 °C(Predicted)
Density  1.33±0.1 g/cm3(Predicted)
storage temp.  Inert atmosphere,Store in freezer, under -20°C
solubility  DMSO (Slightly), Methanol (Slightly)
form  Solid
pka 9.57±0.10(Predicted)
color  Light Brown to Very Dark Brown
Stability: Hygroscopic
CAS DataBase Reference 117976-89-3(CAS DataBase Reference)

Safety information for Rabeprazole

Computed Descriptors for Rabeprazole

Abamectin manufacturer

Synaptics Labs Private Limited

1Y
Phone:+918341963666
Whatsapp: +91 8341963666
product: 2-[[[4-(3-methoxy propoxy)-3-methyl-2-pyridinyl] methyl] sulfinyl]-1H-benzimidazole 117976-89-3 98%
Inquiry

Ions Pharma

1Y
Phone:+91-2266707500
product: Rabeprazole 98%
Inquiry

Sainor Life Sciences Pvt Ltd

1Y
Phone:+919542990009
Whatsapp: +91-9542990009
product: 117976-89-3 98%
Inquiry

Lakshmi Farmachem

1Y
Phone:+91-9550886476
Whatsapp: +91-9550886476
product: Rabeprazole 98%
Inquiry

Indo Rama Pharma

1Y
Phone:+91-9315564742
Whatsapp: +91-9315564742
product: Rabeprazole 117976-89-3 98%
Inquiry

Ralington Pharma

1Y
Phone:+91-9687771722
Whatsapp: +91- 9687771722
product: 117976-89-3 Rabeprazole 98%
Inquiry

PROTECH TELELINKS

1Y
Phone:+91-9855060837
Whatsapp: +91-9855060837
product: 117976-89-3 98%
Inquiry

Lavybens Pharma

1Y
Phone:+91-8790466756
Whatsapp: +91-8790466756
product: Rabeprazole 98%
Inquiry

Alfa Omega Pharma

1Y
Phone:+919972665399
Whatsapp: +91-9972665399
product: Rabeprazole 117976-89-3 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.